Ns. Bese et al., CONTINUOUS HYPERFRACTIONATED ACCELERATED RADIOTHERAPY IN THE TREATMENT OF HIGH-GRADE ASTROCYTOMAS, Radiotherapy and oncology, 47(2), 1998, pp. 197-200
Citations number
21
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Between May 1993 and January 1995, 36 patients with high-grade astrocy
tomas were treated with 1.05 Gy continuous hyperfractionated accelerat
ed radiotherapy three times daily to a total target dose of 59.85 Gy i
n 19 days with 6-h intervals. The median age of the patients was 51 ye
ars and the median follow-up was 58 weeks. The median survival rate wa
s 58 weeks and the cumulative survival rare was 22% at 2 years, No sev
ere toxicity occurred in patients treated with this fractionation sche
me. These results suggest that continuous hyperfractionated accelerate
d radiotherapy is an altered fractionation schedule for: high-grade as
trocytomas with tolerable acute toxicity and survival rates comparable
to conventional fractionation and to other altered fractionation sche
dules. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.